首页> 外文期刊>Drug Design, Development and Therapy >Pharmacokinetics of hard micronized progesterone capsules via vaginal or oral route compared with soft micronized capsules in healthy postmenopausal women: a randomized open-label clinical study
【24h】

Pharmacokinetics of hard micronized progesterone capsules via vaginal or oral route compared with soft micronized capsules in healthy postmenopausal women: a randomized open-label clinical study

机译:健康绝经后妇女通过阴道或口服途径的硬质黄体酮胶囊与软质微粉体胶囊的药代动力学:一项随机开放临床研究

获取原文
       

摘要

Purpose: This study aimed to evaluate the pharmacokinetics of hard micronized progesterone capsules (Yimaxin) via the vaginal or oral route compared with soft micronized progesterone capsules (Utrogestan) in a Chinese population. Methods: A prospective single-center randomized open-label trial was conducted in 16 healthy postmenopausal women. They were randomized into two groups to receive four phases of treatment: vaginal Yimaxin, vaginal Utrogestan, oral Yimaxin, or oral Utrogestan, with different sequences. Results: By the vaginal route, steady-state maximum concentration (Csubmax/sub) of Yimaxin and Utrogestan was 29.13±8.09 and 12.30±1.60 mg/L, time to Csubmax/sub 9.72±10.50 and 11.03±9.62 hours, central compartment volume of distribution 4.26±1.86 and 10.40±2.32 L, clearance rate 0.18±0.05 and 0.38±0.10 L/h, and AUC 261.42±74.36 and 116.83±19.72 h·ng/mL, respectively. By the oral route, Csubmax/sub of Yimaxin and Utrogestan was 62.97±40.59 and 169.53±130.24 mg/L, time to Csubmax/sub was 2.88±1.35 and 2.06±1.55 hours, central compartment volume of distribution 132.16±52.13 and 85.08±55.07 L, clearance rate 3.43±1.07 and 2.50±1.04 L/h, and AUC 274.86±160.28 and 472.00±250.54 h·ng/mL, respectively. By the vaginal route, Csubmax/sub, minimum concentration, AUCsub0–72/sub, and AUC of Yimaxin were higher than Utrogestan, while by the oral route the Csubmax/sub, AUCsub0–72/sub, and AUC of Utrogestan were higher than Yimaxin. Conclusion: Pharmacokinetic parameters were different between Yimaxin and Utrogestan on vaginal and oral administration. By the oral route, the metabolism and absorption of Utrogestan was superior to Yimaxin, while by the vaginal route Yimaxin was superior.
机译:目的:本研究旨在通过阴道或口服途径评估硬微粉孕酮胶囊(Yimaxin)与软微粉孕酮胶囊(Utrogestan)的药代动力学。方法:对16名健康的绝经后妇女进行了一项前瞻性单中心随机开放标签试验。他们被随机分为两组,接受四个阶段的治疗:阴道益马汀,阴道Utrogestan,口服Yimaxin或口服Utrogestan,顺序不同。结果:通过阴道途径,益马辛和Utrogestan的稳态最大浓度(C max )为29.13±8.09​​和12.30±1.60 mg / L,达到C max 的时间9.72±10.50和11.03±9.62小时,中央室分布容积为4.26±1.86和10.40±2.32 L,清除率0.18±0.05和0.38±0.10 L / h,AUC 261.42±74.36和116.83±19.72 h·ng / mL , 分别。通过口服途径,益马辛和Utrogestan的C max 为62.97±40.59和169.53±130.24 mg / L,达到C max 的时间为2.88±1.35和2.06±1.55小时,中央室分布的体积分别为132.16±52.13和85.08±55.07 L,清除率分别为3.43±1.07和2.50±1.04 L / h和AUC 274.86±160.28和472.00±250.54 h·ng / mL。阴道途径中,伊马辛的C max ,最低浓度,AUC 0–72 和AUC均高于Utrogestan,而口服途径的C max ,AUC 0–72 和Utrogestan的AUC均高于Yimaxin。结论:伊马新和Utrogestan在阴道和口服给药时的药代动力学参数不同。通过口服途径,优特孕酮的代谢和吸收优于益马辛,而通过阴道途径,益马辛则更好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号